[
    [
        {
            "time": "",
            "orginal_text": "格隆汇港股聚焦(12.2)︱中国奥园前11月合约销售额升12%至1137.6亿元；东风集团股份与交通银行、武汉经济技术开发区签署协议赋能产业发展",
            "features": {
                "keywords": [
                    "中国奥园",
                    "合约销售额",
                    "东风集团",
                    "交通银行",
                    "武汉经济技术开发区"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "房地产",
                    "汽车",
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "格隆汇港股聚焦(12.2)︱中国奥园前11月合约销售额升12%至1137.6亿元；东风集团股份与交通银行、武汉经济技术开发区签署协议赋能产业发展",
            "scores": {
                "News_content": "格隆汇港股聚焦(12.2)︱中国奥园前11月合约销售额升12%至1137.6亿元；东风集团股份与交通银行、武汉经济技术开发区签署协议赋能产业发展",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "【安信中小盘】立方制药、恒玄科技、航亚科技-次新股资讯1202",
            "features": {
                "keywords": [
                    "立方制药",
                    "恒玄科技",
                    "航亚科技"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "科技"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "original_text": "【安信中小盘】立方制药、恒玄科技、航亚科技-次新股资讯1202",
            "scores": {
                "News_content": "【安信中小盘】立方制药、恒玄科技、航亚科技-次新股资讯1202",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "上海医药(02607)：盐酸贝那普利片及盐酸度洛西汀肠溶胶囊通过仿制药一致性评价",
            "features": {
                "keywords": [
                    "上海医药",
                    "盐酸贝那普利片",
                    "盐酸度洛西汀肠溶胶囊",
                    "仿制药一致性评价"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "上海医药(02607)：盐酸贝那普利片及盐酸度洛西汀肠溶胶囊通过仿制药一致性评价",
            "scores": {
                "News_content": "上海医药(02607)：盐酸贝那普利片及盐酸度洛西汀肠溶胶囊通过仿制药一致性评价",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "恒指收跌0.13% 林业及木材板块领跌",
            "features": {
                "keywords": [
                    "恒指",
                    "林业",
                    "木材板块"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "林业",
                    "木材"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "恒指收跌0.13% 林业及木材板块领跌",
            "scores": {
                "News_content": "恒指收跌0.13% 林业及木材板块领跌",
                "Correlation": 4,
                "Sentiment": 3,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "上海医药(601607.SH)：盐酸贝那普利片及盐酸度洛西汀肠溶胶囊通过仿制药一致性评价",
            "features": {
                "keywords": [
                    "上海医药",
                    "盐酸贝那普利片",
                    "盐酸度洛西汀肠溶胶囊",
                    "仿制药一致性评价"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "上海医药(601607.SH)：盐酸贝那普利片及盐酸度洛西汀肠溶胶囊通过仿制药一致性评价",
            "scores": {
                "News_content": "上海医药(601607.SH)：盐酸贝那普利片及盐酸度洛西汀肠溶胶囊通过仿制药一致性评价",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "交银：关注研发实力强及估值偏低的药企 如康方生物",
            "features": {
                "keywords": [
                    "交银",
                    "研发实力",
                    "估值偏低",
                    "康方生物"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "original_text": "交银：关注研发实力强及估值偏低的药企 如康方生物",
            "scores": {
                "News_content": "交银：关注研发实力强及估值偏低的药企 如康方生物",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]